34 completed, 3 terminated. 18 Phase 4, 11 Phase 2, 6 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 18 | Completed 16, Terminated 2 |
| Phase 2 | 11 | Completed 11 |
| Phase 3 | 6 | Completed 5, Terminated 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Fluzone®: new trials by email Literature Review of Fluzone® trials Research Report on Fluzone®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine - Influenza | Phase 2 | Completed | ModernaTX, Inc. | 172 | 2022-11-02 | 2025-11-24 |
| A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine VXA-A1.1, Fluzone®, Placebo Tablets - Influenza | Phase 2 | Completed | Vaxart | 179 | 2016-08-31 | 2022-10-06 |
| Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children Influenza virus vaccine, Vitamins A and D, Placebo - Healthy Participants | Phase 2 | Completed | St. Jude Children's Research Hospital | 87 | 2016-01-21 | 2019-10-29 |
| Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032) Fluzone®, FluMist® - Influenza | Phase 4 | Terminated | Stanford University | 3 | 2015-09-01 | 2017-05-10 |
| Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031) Fluzone®, FluMist® - Influenza | Phase 4 | Terminated | Stanford University | 10 | 2014-11-19 | 2017-09-12 |
| The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Fluzone®, FluMist® - Influenza, Healthy | Phase 1 | Completed | Stanford University | 80 | 2014-09-30 | 2020-02-13 |
| Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029) Fluzone®, FluMist® - Influenza | Phase 4 | Completed | Stanford University | 77 | 2014-09-17 | 2018-12-14 |
| Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age FluLaval® Quadrivalent, Fluzone® - Influenza | Phase 2 | Completed | GlaxoSmithKline | 316 | 2013-10-23 | 2018-09-07 |
| The Human Mucosal Immune Responses to Influenza Virus (SLVP026) Fluzone®, FluMist® - Influenza | Phase 4 | Completed | Stanford University | 13 | 2012-12-01 | 2017-04-21 |
| A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults High Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine - Influenza | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 31989 | 2011-09-01 | 2015-04-20 |
| Study of Quadrivalent Influenza Vaccine Among Children Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative, Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative, Quadrivalent Influenza Vaccine, No Preservative - Influenza | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 4363 | 2010-11-01 | 2015-07-14 |
| A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age High-Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine - Influenza | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2010-11-01 | 2016-05-16 |
| Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals Fluzone® - HIV Infection | Phase 4 | Completed | University of Pennsylvania | 195 | 2010-11-01 | 2017-04-13 |
| Study of Quadrivalent Influenza Vaccine Among Adults Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative, Investigational Trivalent Inactivated Influenza Vaccine, No Preservative, Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative - Influenza | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 739 | 2010-10-01 | 2013-10-23 |
| Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS) Fluzone® - MELAS Syndrome | Phase 4 | Completed | Stanford University | 22 | 2010-09-01 | 2017-05-30 |
| Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children GSK investigational vaccine GSK1557482A, Fluzone® - Influenza | Phase 3 | Completed | GlaxoSmithKline | 2116 | 2009-10-13 | 2018-09-21 |
| A Study of Influenza Virus Vaccines in Children and Adults 2009-2010 Trivalent Influenza Virus Vaccine, 2008-2009 Trivalent Influenza Virus Vaccine, Quadrivalent Influenza Virus Vaccine - Influenza | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 600 | 2009-10-01 | 2013-12-12 |
| Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine - Influenza | Phase 3 | Terminated | Sanofi | 9172 | 2009-09-01 | 2012-08-01 |
| Influenza Vaccine in Pregnant Women Fluzone®, Fluarix® - Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 102 | 2009-06-01 | 2012-06-13 |
| Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults Influenza Virus Vaccine USP Trivalent Types A and B - Orthomyxoviridae Infection, Influenza | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 4292 | 2008-10-01 | 2016-04-14 |
Showing 20 of 37. Sign in to see all of them.
Influenza, Human (36) · Orthomyxoviridae Infections (3) · HIV Infections (1) · MELAS Syndrome (1) · Mitochondrial Diseases (1) · Respiratory Tract Infections (1)
Sanofi Pasteur, a Sanofi Company (19) · Stanford University (6) · GlaxoSmithKline (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Sanofi (2) · ModernaTX, Inc. (1) · St. Jude Children's Research Hospital (1) · University of Pennsylvania (1) · Vaxart (1)
United States (34) · Puerto Rico (3) · Canada (1)
Cornelia Dekker, MD (4) · Cornelia L Dekker, MD (2) · Harry Greenberg, MD (2) · Mark Davis, PhD (2) · Xiaosong He, PhD (2) · Gregory M Enns, MBChB (1) · K. Christopher Garcia, PhD (1) · Mark M Davis, PhD (1) · Nehali Patel, MD (1) · Philip M Grant, MD (1)
PMID 16220095, PMID 21352939, PMID 22333695, PMID 23277897, PMID 23499604, PMID 24120672, PMID 24445833, PMID 25119609, PMID 26762363, PMID 27669017, PMID 29465480, PMID 31978354, PMID 33632249
U19AI057229 (4), R21HD061709 (1), U19AI090019 (1)